Forte Biosciences Inc. (FBRX)
NASDAQ:FBRX
Want to see FBRX full AI Analyst Report?
FBRX Stock Chart & Stats
$33.92
-$0.92(-4.43%)
At close: 4:00 PM EST
$33.92
-$0.92(-4.43%)
Day’s Range― - ―
52-Week Range$9.10 - $35.80
Previous CloseN/A
Volume20.10K
Average Volume (3M)97.46K
Market Cap
$365.55M
Enterprise Value$186.03M
Total Cash (Recent Filing)$58.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 17, 2026EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.58
Shares Outstanding20,478,817
10 Day Avg. Volume83,173
30 Day Avg. Volume97,456
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)65.81
Price to Sales (P/S)0.00
P/FCF Ratio-78.70
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-31.00K
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$67.00Price Target Upside97.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt capital structure materially reduces financing cost risk and interest obligations, giving Forte durable financial flexibility to fund R&D. For a pre-revenue biotech, no debt lowers bankruptcy risk and preserves optionality to prioritize clinical programs over near-term cash returns.
$150M Public Offering And Strategic StakeThe ~$141M net proceeds from the April offering materially extend runway for clinical programs like FB102 and reduce immediate financing urgency. Argenx's strategic stake provides validation and potential partnership optionality, strengthening Forte's ability to advance trials and attract collaborators.
Governance Continuity And Incentive PlanRe-election of directors, ratification of auditors, and an updated equity incentive plan signal stable governance and aligned management incentives. Strong governance and retention tools support consistent execution of a clinical development strategy over the medium term.
Bears Say
No Revenue And Widening LossesForte's lack of operating revenue and escalating net losses are structural for a clinical-stage biopharma but mean the company cannot self-fund operations. Ongoing negative earnings require repeated external capital raises, increasing dilution risk and making long-term sustainability contingent on clinical success or partnerships.
Deeply Negative Operating And Free Cash FlowSustained negative operating and free cash flow indicate the business is consuming cash to progress trials rather than generating it. Even with recent financing, persistent burn means recurring capital raises are likely, creating execution risk if future financing conditions tighten or trial milestones are missed.
Declining Equity And Assets (runway Consumption)Declining equity and asset bases reflect cumulative losses and cash consumption, reducing balance-sheet optionality. For a drug developer, a shrinking asset base limits strategic flexibility to fund multiple programs or respond to setbacks without dilutive financings or partner transactions.
Forte Biosciences News
FBRX FAQ
What was Forte Biosciences Inc.’s price range in the past 12 months?
Forte Biosciences Inc. lowest stock price was $9.10 and its highest was $35.80 in the past 12 months.
What is Forte Biosciences Inc.’s market cap?
Forte Biosciences Inc.’s market cap is $365.55M.
When is Forte Biosciences Inc.’s upcoming earnings report date?
Forte Biosciences Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were Forte Biosciences Inc.’s earnings last quarter?
Forte Biosciences Inc. released its earnings results on May 11, 2026. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.24.
Is Forte Biosciences Inc. overvalued?
According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued.
Does Forte Biosciences Inc. pay dividends?
Forte Biosciences Inc. does not currently pay dividends.
What is Forte Biosciences Inc.’s EPS estimate?
Forte Biosciences Inc.’s EPS estimate is -1.03.
How many shares outstanding does Forte Biosciences Inc. have?
Forte Biosciences Inc. has 20,478,817 shares outstanding.
What happened to Forte Biosciences Inc.’s price movement after its last earnings report?
Forte Biosciences Inc. reported an EPS of -$1.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.243%.
Which hedge fund is a major shareholder of Forte Biosciences Inc.?
Currently, no hedge funds are holding shares in FBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Forte Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.00 (97.52% Upside)
$67.00 (97.52% Upside)
Blogger Sentiment
Bullish
FBRX Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.71%
12-Months-Change
Fundamentals
Return on Equity
-106.16%
Trailing 12-Months
Asset Growth
41.64%
Trailing 12-Months
Company Description
Forte Biosciences Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
FBRX Stock 12 Month Forecast
Average Price Target
$67.00
▲(97.52% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protalix
―
Protara Therapeutics
―
Innate Pharma
―
Ownership Overview
1.83% Insiders
18.85% Mutual Funds
35.53% Other Institutional Investors
39.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---